BA 1 is a potent bombesin receptor agonist (IC50 values are 0.26, 1.55 and 2.52 nM for BB1, BB2 and BB3 respectively). BA 1 enhances glucose transport in obese and diabetic primary myocytes. BA 1 also stimulates NCI-H1299 lung cancer cell proliferation in vitro.

Spadin TFA, a natural peptide derived from a propeptide released in blood, is able to block the TREK-1 (KCNK2 or K2P2.1) channel activity. Spadin TFA binds specifically to TREK-1 with an affinity of 10 nM. Spadin TFA is an efficient antidepressant in mice.

Spadin, a natural peptide derived from a propeptide released in blood, is able to block the TREK-1 (KCNK2 or K2P2.1) channel activity. Spadin binds specifically to TREK-1 with an affinity of 10 nM. Spadin is an efficient antidepressant in mice.

TAT-cyclo-CLLFVY is a selective HIF-1 dimerization inhibitor. TAT-cyclo-CLLFVY blocks protein-protein interaction of recombinant HIF-1α, but not HIF-2α, with HIF-1β (IC50=1.3 μM). TAT-cyclo-CLLFVY inhibits hypoxia-induced HIF-1 activity, and decreases VEGF and CAIX expression in osteosarcoma and breast cancer cells in vitro. TAT-cyclo-CLLFVY also reduces tubularization of hypoxic HUVECs.

AP 811 is a selective atrial natriuretic peptide clearance receptor (APN-CR, NPR3) antagonist (Ki=0.48 nM). AP 811 displays >20,000-fold selectivity for NPR3 over NPR1. AP 811 abolishes ANP-induced pump stimulation.

DPC-AJ1951 TFA, a 14 amino acid peptide that acts as a potent agonist of the parathyroid hormone (PTH)/PTH-related peptide receptor (PPR) , and characterized its activity in ex vivo and in vivo assays of bone resorption.

GRK2i is a GRK2 inhibitory polypeptide that specifically inhibits Gβγ activation of GRK2. GRK2i corresponds to the Gβγ-binding domain and acts as a cellular Gβγ antagonist.

AC 187 TFA is an orally active, potent amylin receptor antagonist (IC50= 0.48 nM) that displays 38-fold and 400-fold selectivity over calcitonin and CGRP receptors respectively. AC 187 TFA blocks amyloid β-induced neurotoxicity by attenuating the activation of initiator and effector caspases in vitro. AC 187 TFA increases glucagon secretion, accelerates gastric emptying, alters plasma glucose levels and increases food intake in vivo.

AC 187 is an orally active, potent amylin receptor antagonist (IC50= 0.48 nM) that displays 38-fold and 400-fold selectivity over calcitonin and CGRP receptors respectively. AC 187 blocks amyloid β-induced neurotoxicity by attenuating the activation of initiator and effector caspases in vitro. AC 187 increases glucagon secretion, accelerates gastric emptying, alters plasma glucose levels and increases food intake in vivo.

ZIP(Scrambled) TFA is a scrambled control peptide for zeta inhibitory peptide (ZIP).

ZIP(Scrambled) is a scrambled control peptide for zeta inhibitory peptide (ZIP).

d[Cha4]-AVP TFA is a potent and selective human vasopressin V1B receptor agonist (Ki values are 1.2, 151, 240 and 750 nM for V1B, V1A, Oxytocin and V2 receptors respectively). d[Cha4]-AVP TFA stimulates ACTH and corticosterone secretion and exhibits negligible vasopressor activity in vivo.

d[Cha4]-AVP is a potent and selective human vasopressin V1B receptor agonist (Ki values are 1.2, 151, 240 and 750 nM for V1B, V1A, Oxytocin and V2 receptors respectively). d[Cha4]-AVP stimulates ACTH and corticosterone secretion and exhibits negligible vasopressor activity in vivo.

Neuropeptide S human is a potent endogenous neuropeptide S receptor agonist (EC50= 9.4 nM). Neuropeptide S human increases locomotor activity and wakefulness in mice. Neuropeptide S human also reduces anxiety-like behavior in mice.

Rac1 Inhibitor F56, control peptide TFA is a control peptide version of Rac1 Inhibitor. Rac1 Inhibitor F56, control peptide comprises residues 45-60 of Rac1 with Trp56 replaced by Phe. Rac1 Inhibitor F56, control peptide TFA does not affect GEF-Rac1 interaction.

Rac1 Inhibitor F56, control peptide is a control peptide version of Rac1 Inhibitor. Rac1 Inhibitor F56, control peptide comprises residues 45-60 of Rac1 with Trp56 replaced by Phe. Rac1 Inhibitor F56, control peptide does not affect GEF-Rac1 interaction.

Rac1 Inhibitor W56 TFA is a peptide comprising residues 45-60 of the guanine nucleotide exchange factor (GEF) recognition/activation site of Rac1. Rac1 Inhibitor W56 TFA selectively inhibits Rac1 interaction with Rac1-specific GEFs TrioN, GEF-H1 and Tiam1.

Rac1 Inhibitor W56 is a peptide comprising residues 45-60 of the guanine nucleotide exchange factor (GEF) recognition/activation site of Rac1. Rac1 Inhibitor W56 selectively inhibits Rac1 interaction with Rac1-specific GEFs TrioN, GEF-H1 and Tiam1.

Amyloid β-Peptide(1-43) human TFA, the Human β-amyloid peptide, is minor component of neuritic plaques found in brains of patients with Alzheimer's disease.

Amyloid β-Peptide(1-43) human, the Human β-amyloid peptide, is minor component of neuritic plaques found in brains of patients with Alzheimer's disease.

Caffeic acid-pYEEIE TFA, a non-phosphopeptide inhibitor, exhibits potent binding affinity for the GST-Lck-SH2 domain.

Caffeic acid-pYEEIE, a non-phosphopeptide inhibitor, exhibits potent binding affinity for the GST-Lck-SH2 domain.

G-Protein antagonist peptide TFA is the substance P-related peptide that inhibits binding of G proteins to their receptors. G-Protein antagonist peptide TFA competitively and reversibly inhibits M2 muscarinic receptor activation of Gi or Go and inhibits Gs activation by β-adrenoceptors.

G-Protein antagonist peptide is the substance P-related peptide that inhibits binding of G proteins to their receptors. G-Protein antagonist peptide competitively and reversibly inhibits M2 muscarinic receptor activation of Gi or Go and inhibits Gs activation by β-adrenoceptors.

[D-Trp7,9,10]-Substance P TFA is the substance P analog that inhibits activation of Gq/11 by M1 muscarinic ACh receptors. [D-Trp7,9,10]-Substance P TFA does not inhibit Gi/o activation by M2 ACh receptors.

[D-Trp7,9,10]-Substance P is the substance P analog that inhibits activation of Gq/11 by M1 muscarinic ACh receptors. [D-Trp7,9,10]-Substance P does not inhibit Gi/o activation by M2 ACh receptors.

DynaMin inhibitory peptide, myristoylated TFA is a DynaMin inhibitor to interfere with the binding of amphiphysin with dynamin. DynaMin inhibitory peptide, myristoylated TFA is a membrane-permeant form of the peptide that prevents endocytosis.

DynaMin inhibitory peptide, myristoylated is a DynaMin inhibitor to interfere with the binding of amphiphysin with dynamin. DynaMin inhibitory peptide, myristoylated is a membrane-permeant form of the peptide that prevents endocytosis.

des-Gln14-Ghrelin TFA is a second endogenous ligand for the growth hormone secretagogue receptor. a). des-Gln14-ghrelin potently induces increases in [Ca2+]i in CHO-GHSR62 cells, with an EC50 of 2.4 nM.

des-Gln14-Ghrelin is a second endogenous ligand for the growth hormone secretagogue receptor. a). des-Gln14-ghrelin potently induces increases in [Ca2+]i in CHO-GHSR62 cells, with an EC50 of 2.4 nM.